Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2023 06:30 ET | Source: Oculis Holding AG

Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update

Achieved two landmark milestones with OCS-01, Oculis’ lead product candidate as first investigational eye drop for both front and back of the eye indications: positive topline results in Phase 3...
August 08, 2023 06:30 ET | Source: Oculis Holding AG

OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery

Once daily OCS-01 meets primary endpoints demonstrating superior reduction in inflammation and pain vs. vehicle following cataract surgeryOPTIMIZE’s results follow the positive and statistically...
August 02, 2023 08:00 ET | Source: Oculis Operations Sarl

First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema

LEOPARD trial initiation follows recent positive data from OCS-01 eye drops from the Stage 1 Phase 3 DIAMOND trial in patients with Diabetic Macular Edema (DME)Cystoid Macular Edema (CME) can result...
July 26, 2023 08:00 ET | Source: Oculis SA

Oculis Announces to Present at Upcoming August Investor Conferences

ZUG, Switzerland, and BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
July 19, 2023 08:00 ET | Source: Oculis SA

Oculis to Present at OIS Retina Innovation Summit

ZUG, Switzerland, and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
June 26, 2023 08:00 ET | Source: Oculis SA

Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023

R&D Retina Day featuring several retina experts will take place from 10:00 AM – 12:00 PM EDT at the Lotte New York Palace Hotel and onlineCo-principal investigators, Dr. David S. Boyer and Dr....
June 13, 2023 16:01 ET | Source: Oculis SA

Oculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares

ZUG, Switzerland and BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
June 12, 2023 08:00 ET | Source: Oculis SA

Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics

The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders Professors Einar Stefánsson, and Thorsteinn Loftsson. OPTIREACH is behind Oculis’...
June 01, 2023 08:00 ET | Source: Oculis SA

Oculis to Participate in Jefferies Healthcare Conference

ZUG, Switzerland and BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
May 31, 2023 23:59 ET | Source: Oculis SA

Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares

ZUG, Switzerland and BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...